Latest News

Antares Pharma Stock Soars After $960 Million Halozyme Buyout

0
Text size

Nasdaq-listed Antares Pharma is being bought by Halozyme Therapeutics in a deal valued at $960 million.

Michael Nagle/Bloomberg

Shares of


Antares Pharma

surged more than 47% in premarket trading Wednesday after the specialty pharmaceutical company agreed to be bought by


Halozyme Therapeutics

 in a cash deal valued at $960 million.

Under terms of the deal, Halozyme (ticker: HALO) will pay $5.60 a share to buy Antares (ATRS), the company said in a statement. That represents a 49.7% premium to Tuesday’s closing price of $3.74.

Antares stock, which has risen 4.76% in the year to date, rose more than $47% in premarket trading to $5.50.

Halozyme said that it expects the deal, which is expected to close in the first half of 2022, to immediately add to 2022 revenue and adjusted earnings per share, and accelerate revenue and earnings growth through 2027. 

“The addition of Antares, particularly with its best-in-class auto injector platform and specialty commercial business, augments Halozyme’s strategy, further strengthens our position as a leading drug delivery company and extends our strategy to include specialty products,” said Helen Torley, Halozyme chief executive.

Write to Lina Saigol at lina.saigol@dowjones.com

Inflation Capped in USA, Overshoots in UK

Previous article

Delta reports Q1 loss, raises guidance amid ‘all time high’ demand

Next article

You may also like

Comments

Leave a reply

Your email address will not be published.

More in Latest News